MarketLens
Sign Up

Why is Aurinia Pharmaceuticals Acquiring Kezar Life Sciences

4 months ago
SHARE THIS ON:

Why is Aurinia Pharmaceuticals Acquiring Kezar Life Sciences

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News4 days ago

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled voclosporin patent litigation with Teva, delaying potential U.S. generic competition until December 2036. The settlement removes near-term patent risk and supports the ...
Stock News1 months ago

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Jasper Therapeutics will merge with Kira Pharmaceuticals, creating a combined entity focused on advancing biologic agents for immunologically-driven disorders.
Stock News1 months ago

Why This Pharmaceutical Stock Jumped Close to 100% This Week

Shares of a pharmaceutical stock surged nearly 100% this week after agreeing to be acquired by a larger sector firm.
Stock News1 months ago

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks acquired Theravance Biopharma for $929M, gaining Yupelri's ~$60M annual cash flows with patent protection to 2039, diversifying beyond oncology and reducing equity reliance.

Breaking News

View All →

Top Headlines

View More →
Stock News48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News1 hour ago

Q2 Earnings Season Winds Down: 3 Companies That Broke Records